{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:42:26Z","timestamp":1762605746631,"version":"build-2065373602"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002905","name":"Gobierno de Colombia Ministerio de Salud y Proteccion Social","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vhri.2024.101073","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T20:09:29Z","timestamp":1738786169000},"page":"101073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia"],"prefix":"10.1016","volume":"47","author":[{"given":"Luis Esteban Orozco","family":"Ramirez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Fernando \u00c1vila","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Camilo Anzola","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz Karime Osorio","family":"Arango","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merideidy","family":"Plazas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan Dar\u00edo","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.vhri.2024.101073_bib1","first-page":"S81","article-title":"Diagnosis and classification of diabetes mellitus","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.vhri.2024.101073_bib2","first-page":"1","article-title":"Situaci\u00f3n de la enfermedad renal cr\u00f3nica, la hipertensi\u00f3n arterial y la diabetes mellitus en Colombia 2020","volume":"152","year":"2021","journal-title":"Cuenta Alto Costo"},{"key":"10.1016\/j.vhri.2024.101073_bib3","first-page":"82","article-title":"Impacto del alto costo relacionado con la diabetes mellitus en el sistema de salud en Colombia","volume":"2","author":"Jaimes","year":"2019","journal-title":"REDIIS. Rev Investig"},{"year":"2019","series-title":"Informe T\u00e9cnico de Posicionamiento Terap\u00e9utico Para el Tratamiento Farmacol\u00f3gico de la Diabetes Mellitus Tipo 1 y Tipo 2 con Insulinas y An\u00e1logos de Insulinas","author":"Orozco","key":"10.1016\/j.vhri.2024.101073_bib4"},{"article-title":"Gu\u00eda de Pr\u00e1ctica Cl\u00ednica Para el Diagn\u00f3stico","year":"2016","series-title":"Tratamiento y Seguimiento de la Diabetes Mellitus Tipo 2 en la Poblaci\u00f3n Mayor de 18 A\u00f1os","key":"10.1016\/j.vhri.2024.101073_bib5"},{"key":"10.1016\/j.vhri.2024.101073_bib6","article-title":"Cl\u00ednica Para el Diagn\u00f3stico, Tratamiento y Seguimiento de los Pacientes Mayores de 15 A\u00f1os con Diabetes Mellitus Tipo 1. Bogot\u00e1 D.C","author":"Gu\u00eda de Pr\u00e1ctica","year":"2015","journal-title":"Ministerio de Salud y Protecci\u00f3n Social"},{"year":"2014","series-title":"Manual Para la Elaboraci\u00f3n de Evaluaciones Econ\u00f3micas en Salud","author":"Moreno","key":"10.1016\/j.vhri.2024.101073_bib8"},{"issue":"4","key":"10.1016\/j.vhri.2024.101073_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1503\/cmaj.081041","article-title":"Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis","volume":"180","author":"Singh","year":"2009","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.vhri.2024.101073_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.20452\/pamw.2922","article-title":"Corrections: clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"125","author":"Wojciechowski","year":"2015","journal-title":"Pol Arch Med Wewn"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2337\/diacare.25.3.439","article-title":"Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes","volume":"25","author":"Bode","year":"2002","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.vhri.2024.101073_bib12","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1464-5491.2000.00380.x","article-title":"Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial","volume":"17","author":"Home","year":"2000","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib13","first-page":"CD006297","article-title":"Intermediate acting versus long acting insulin for type 1 diabetes mellitus","volume":"2008","author":"Moshe","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.vhri.2024.101073_bib14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1463-1326.2008.00976.x","article-title":"Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis","volume":"11","author":"Monami","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.vhri.2024.101073_bib15","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2337\/diacare.23.5.639","article-title":"Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes","volume":"23","author":"Ratner","year":"2000","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.vhri.2024.101073_bib16","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2337\/diacare.23.11.1666","article-title":"A\u00a016-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes","volume":"23","author":"Raskin","year":"2000","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1464-5491.2005.01781.x","article-title":"Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes","volume":"23","author":"Ashwell","year":"2006","journal-title":"Diabet Med"},{"issue":"9","key":"10.1016\/j.vhri.2024.101073_bib18","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1445-5994.2005.00902.x","article-title":"Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy","volume":"35","author":"Fulcher","year":"2005","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2337\/diacare.23.2.157","article-title":"Efficacy and safety of HOE 901 versus NPH Insulin in patients with type 1 diabetes","volume":"23","author":"Pieber","year":"2000","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.vhri.2024.101073_bib20","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/dmrr.572","article-title":"A\u00a0randomized multicentre trial of insulin glargine compared with NPH Insulin in people with type 1 diabetes","volume":"21","author":"Home","year":"2005","journal-title":"Diabetes Metab Res Rev"},{"issue":"8","key":"10.1016\/j.vhri.2024.101073_bib21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/pedi.12051","article-title":"A\u00a0randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH Insulin (the PRESCHOOL study)","volume":"14","author":"Danne","year":"2013","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"10.1016\/j.vhri.2024.101073_bib22","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0149-2918(04)90072-0","article-title":"Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen","volume":"26","author":"Russell-Jones","year":"2004","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.vhri.2024.101073_bib23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/dia.2004.6.579","article-title":"The 12-month efficacy and safety of insulin detemir and NPH Insulin in basal-bolus therapy for the treatment of type 1 diabetes","volume":"6","author":"Standl","year":"2004","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"10.1016\/j.vhri.2024.101073_bib24","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1464-5491.2005.01545.x","article-title":"Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH Insulin","volume":"22","author":"Pieber","year":"2005","journal-title":"Diabet Med"},{"issue":"4","key":"10.1016\/j.vhri.2024.101073_bib25","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1464-5491.2007.02407.x","article-title":"Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial","volume":"25","author":"Bartley","year":"2008","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.vhri.2024.101073_bib26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4158\/EP.10.1.10","article-title":"Once-daily insulin glargine compared with twice-daily NPH Insulin in patients with type 1 diabetes","volume":"10","author":"Hershon","year":"2004","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib27","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/dme.12041","article-title":"Insulin analogues in children with type 1 diabetes: a 52-week randomized clinical trial","volume":"30","author":"Thalange","year":"2013","journal-title":"Diabet Med"},{"issue":"7","key":"10.1016\/j.vhri.2024.101073_bib28","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1464-5491.2006.01862.x","article-title":"Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH Insulin in type 1 diabetes","volume":"23","author":"K\u00f8lendorf","year":"2006","journal-title":"Diabet Med"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1177\/0145721706288255","article-title":"Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control","volume":"32","author":"Robertson","year":"2006","journal-title":"Diabetes Educ"},{"key":"10.1016\/j.vhri.2024.101073_bib30","article-title":"Efficacy and Safety of insulin Degludec versus insulin glargine: a systematic review and meta-analysis of fifteen clinical trials","author":"Liu","year":"2018","journal-title":"Int J Endocrinol"},{"issue":"4","key":"10.1016\/j.vhri.2024.101073_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1185\/03007995.2013.772507","article-title":"Efficacy and safety of degludec insulin: a meta-analysis of randomised trials","volume":"29","author":"Monami","year":"2013","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib32","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1210\/jc.2012-3249","article-title":"Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension","volume":"98","author":"Mathieu","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib33","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jval.2017.04.024","article-title":"Basal insulin regimens for adults with type 1 diabetes mellitus: a systematic review and network meta-analysis","volume":"21","author":"Dawoud","year":"2018","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.vhri.2024.101073_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00125-004-1365-z","article-title":"Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH Insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes","volume":"47","author":"Hermansen","year":"2004","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.vhri.2024.101073_bib35","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2337\/diacare.27.5.1081","article-title":"Insulin detemir Offers Improved glycemic Control Compared with NPH Insulin in People with type 1 diabetes: a randomized clinical trial","volume":"27","author":"Home","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib36","article-title":"Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus","volume":"2","author":"Siebenhofer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib37","article-title":"Long-acting insulin analogues versus NPH Insulin (human isophane insulin) for type 2 diabetes mellitus","volume":"2","author":"Horvath","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.vhri.2024.101073_bib38","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1111\/j.1464-5491.2008.02517.x","article-title":"Safety and efficacy of glargine compared with NPH Insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"25","author":"Bazzano","year":"2008","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.vhri.2024.101073_bib39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00592-018-1107-1","article-title":"Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"55","author":"Zhang","year":"2018","journal-title":"Acta Diabetol"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009421","article-title":"Safety and efficacy of insulin glargine 300 u\/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis","volume":"6","author":"Freemantle","year":"2016","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.vhri.2024.101073_bib41","article-title":"Insulin detemir versus insulin glargine for type 2 diabetes mellitus","volume":"2017","author":"Swinnen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.vhri.2024.101073_bib42","article-title":"Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus","volume":"6","author":"Fullerton","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.vhri.2024.101073_bib43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/dmrr.989","article-title":"Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes","volume":"25","author":"Raskin","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"issue":"4","key":"10.1016\/j.vhri.2024.101073_bib44","first-page":"340","article-title":"An indirect treatment comparison of the efficacy of insulin degludec\/liraglutide (IDegLira) and insulin glargine\/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin","volume":"21","author":"Evans","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"10","key":"10.1016\/j.vhri.2024.101073_bib45","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/BF02374494","volume":"36","year":"1993","journal-title":"Diabetologia"},{"key":"10.1016\/j.vhri.2024.101073_bib46","article-title":"Risk factors for microvascular complications of diabetes in a high-risk middle east population","volume":"2018","author":"Cheema","year":"2018","journal-title":"J\u00a0Diabetes Res"},{"issue":"6","key":"10.1016\/j.vhri.2024.101073_bib47","first-page":"313","article-title":"Analisis coste-utilidad del tratamiento de la diabetes mellitus con insulina glargina o insulina NPH en Espa\u00f1a","volume":"2","author":"Rubio-Terr\u00e9s","year":"2003","journal-title":"Rev Espa\u00f1ola Econ Salud"},{"issue":"1","key":"10.1016\/j.vhri.2024.101073_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/nep.13203","article-title":"Cost-utility analysis of the National Health Screening Program for chronic kidney disease in Korea","volume":"24","author":"Go","year":"2019","journal-title":"Nephrology"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib49","article-title":"Cost-effectiveness of intensifying lipid-lowering therapy with statins based on individual absolute benefit in coronary artery disease patients","volume":"6","author":"Stam-Slob","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.vhri.2024.101073_bib50","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc11-2478","article-title":"Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from translating research into action for diabetes (TRIAD)","volume":"35","author":"Zhang","year":"2012","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.vhri.2024.101073_bib51","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40273-016-0433-9","article-title":"Cost effectiveness of IDegLira vs. alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting","volume":"34","author":"Davies","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.vhri.2024.101073_bib52","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/0272989X18803109","article-title":"Cost-effectiveness of initiating an insulin pump in T1D adults using continuous glucose monitoring compared with multiple daily insulin injections: the DIAMOND randomized trial","volume":"38","author":"Wan","year":"2018","journal-title":"Med Decis Mak Int J Soc Med Decis Mak"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib53","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/heapol\/czab146","article-title":"Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia","volume":"37","author":"Espinosa","year":"2022","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.vhri.2024.101073_bib55","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vhri.2016.10.006","article-title":"Cost effectiveness of dulaglutide compared with liraglutide and glargine in type 2 diabetes mellitus patients in Colombia","volume":"14","author":"Lasalvia","year":"2017","journal-title":"Value Health Reg Issues"},{"issue":"28","key":"10.1016\/j.vhri.2024.101073_bib56","first-page":"190","article-title":"An\u00e1lisis de costo-utilidad del uso de detemir en pacientes con diabetes tipo 2","volume":"14","author":"Romero-Prada","year":"2015","journal-title":"Rev Gerencia Pol Salud"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib57","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7705\/biomedica.v35i2.2338","article-title":"An\u00e1lisis comparativo de insulina glargina frente a la insulina detemir: un modelo de minimizaci\u00f3n de costos aplicable en Colombia","volume":"35","author":"Fragozo","year":"2015","journal-title":"Biom\u00e9dica"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib58","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902017000300178","article-title":"Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system","volume":"53","author":"Cazarim","year":"2017","journal-title":"Braz J Pharm Sci"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00019053-200725030-00007","article-title":"Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada","volume":"25","author":"Grima","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.vhri.2024.101073_bib60","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14737167.2017.1345628","article-title":"Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus\u2013from the Spanish National Health System perspective","volume":"17","author":"Mezquita-Raya","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"suppl 2","key":"10.1016\/j.vhri.2024.101073_bib61","first-page":"14","article-title":"Health economic evaluation of insulin glargine vs NPH Insulin in intensified conventional therapy for type 1 diabetes in Germany","volume":"15","author":"Pfohl","year":"2012","journal-title":"J\u00a0Med Econ"},{"issue":"3","key":"10.1016\/j.vhri.2024.101073_bib62","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40258-018-0379-5","article-title":"Treating type 1 diabetes mellitus with a rapid-acting analog insulin regimen vs. regular human insulin in Germany: a long-term cost-effectiveness evaluation","volume":"16","author":"Valentine","year":"2018","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"10.1016\/j.vhri.2024.101073_bib63","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s13300-017-0236-9","article-title":"Cost-effectiveness of insulin degludec versus insulin glargine in adults with type 1 and type 2 diabetes mellitus","volume":"8","author":"Evans","year":"2017","journal-title":"Diabetes Ther"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2024.101073_bib64","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1185\/030079907X167561","article-title":"Evaluation of the cost-effectiveness of insulin glargine versus NPH Insulin for the treatment of type 1 diabetes in the UK","volume":"23","author":"McEwan","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.vhri.2024.101073_bib65","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1185\/030079908X297295","article-title":"Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study","volume":"24","author":"Palmer","year":"2008","journal-title":"Curr Med Res Opin"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924001067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924001067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:34:18Z","timestamp":1762605258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924001067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":63,"alternative-id":["S2212109924001067"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101073","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101073"}}